JW (Cayman) Therapeutics Co (HKSE:02126) Median PS Value : HK$0.00 (As of Jun. 05, 2024)

View and export this data going back to 2020. Start your Free Trial

What is JW (Cayman) Therapeutics Co Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. JW (Cayman) Therapeutics Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.449. JW (Cayman) Therapeutics Co's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is HK$0.00.

As of today (2024-06-05), JW (Cayman) Therapeutics Co's share price is HK$2.32. JW (Cayman) Therapeutics Co's Median PS Value is HK$0.00. Therefore, JW (Cayman) Therapeutics Co's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for JW (Cayman) Therapeutics Co's Median PS Value or its related term are showing as below:

HKSE:02126's Price-to-Median-PS-Value is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.67
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

JW (Cayman) Therapeutics Co Median PS Value Historical Data

The historical data trend for JW (Cayman) Therapeutics Co's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

JW (Cayman) Therapeutics Co Median PS Value Chart

JW (Cayman) Therapeutics Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Median PS Value

Get a 7-Day Free Trial

JW (Cayman) Therapeutics Co Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Median PS Value	Get a 7-Day Free Trial						-	-	-	-	-

Competitive Comparison of JW (Cayman) Therapeutics Co's Median PS Value

For the Biotechnology subindustry, JW (Cayman) Therapeutics Co's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

JW (Cayman) Therapeutics Co's Price-to-Median-PS-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, JW (Cayman) Therapeutics Co's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where JW (Cayman) Therapeutics Co's Price-to-Median-PS-Value falls into.

JW (Cayman) Therapeutics Co Median PS Value Calculation

JW (Cayman) Therapeutics Co's Median PS Value for today is calculated as

Median PS Value	=	Revenue per Share (TTM)	*	10-Year Median PS Ratio
	=	0.449	*	0
	=	0.00

10-Year Median PS Ratio is 0.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. JW (Cayman) Therapeutics Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.449.

JW (Cayman) Therapeutics Co (HKSE:02126) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

JW (Cayman) Therapeutics Co's Price to Median PS Value for today is calculated as

Price to Median PS Value	=	Share Price	/	Median PS Value
	=	2.32	/	0.00
	=

JW (Cayman) Therapeutics Co Median PS Value Related Terms

Thank you for viewing the detailed overview of JW (Cayman) Therapeutics Co's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.

JW (Cayman) Therapeutics Co (HKSE:02126) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » JW (Cayman) Therapeutics Co Ltd (HKSE:02126) » Definitions » Median PS Value

Comparable Companies

Traded in Other Exchanges

JWCTF:USA

Address

No. 699 Zhong Ke Road, 5F, Building B, Pudong New District, Shanghai, CHN

Website

https://www.jwtherapeutics.com

JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.

Executives

Li Dan	2202 Interest of your spouse
Li Yiping James	2201 Interest of corporation controlled by you
Syracuse Biopharma (cayman) Ii, Ltd.	2501 Other
Bristol-myers Squibb Company	2201 Interest of corporation controlled by you
Celgene Corporation	2201 Interest of corporation controlled by you
Juno Therapeutics, Inc.	2101 Beneficial owner
Syracuse Biopharma (cayman) Ltd.	2501 Other

JW (Cayman) Therapeutics Co (HKSE:02126) Headlines

No Headlines